Status:
NOT_YET_RECRUITING
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Lead Sponsor:
Eli Lilly and Company
Conditions:
Chronic Lymphocytic Leukemia
Lymphoma, Small Lymphocytic
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to thos...
Eligibility Criteria
Inclusion
- Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020
Exclusion
- This is not applicable to this study
Key Trial Info
Start Date :
March 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2032
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT07218341
Start Date
March 1 2026
End Date
December 1 2032
Last Update
December 17 2025
Active Locations (50)
Enter a location and click search to find clinical trials sorted by distance.
1
Mitchell Cancer Institute
Mobile, Alabama, United States, 36693
2
Arizona Oncology Associates, P.C. - HOPE
Tucson, Arizona, United States, 85711
3
Cancer Specialists, LLC
Jacksonville, Florida, United States, 32256
4
University of Maryland
Baltimore, Maryland, United States, 21201